Syngene offers SARS-CoV-2 in-vitro and in-vivo research, in partnership with Foundation for Neglected Disease Research (FNDR). This non-exclusive partnership, aims to provide a range of non-BSL3 and BSL3 in vitro and in vivo capabilities to facilitate a wide variety of studies on SARS-CoV-2, and prepare us for the next wave of the corona virus pandemic.
Our joint offerings include:
Oligonucleotide therapeutics is one of the most promising ﬁelds in modern medicine to treat several diseases which are genetic or non-genetic in nature by modulating gene expression.
Oligos face immense challenges for their use as therapeutics and these challenges must be resolved before proceeding with regulatory approvals. Since a highly complex nature of oligo drugs mandates novel and sophisticated process methods, Syngene has a complete dedicated facility for oligos which satisfy the cGMP requirements.